Day: February 26, 2026

Brink’s to Acquire NCR Atleos for $6.6 Billion, Creating Leading Financial Technology Infrastructure Company

Written by Customer Service on February 26, 2026. Posted in Mergers And Acquisitions.

Cash and stock transaction combines two complementary trusted and globally recognized financial technology infrastructure providers to better serve banking and retail customers Positioned to accelerate Brink’s growth in high-margin AMS and DRS businesses by expanding into large, under-penetrated addressable markets Expected to deliver at least 35% accretion to EPS, while generating strong cash flow with an estimated $200 million in annual run-rate cost synergies RICHMOND, Va. and ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) — The Brink’s Company (NYSE: BCO) (“Brink’s”) and NCR Atleos Corporation (NYSE: NATL) (“NCR Atleos”) today announced that they have entered into a definitive agreement under which Brink’s will acquire NCR Atleos in a cash and stock transaction valued at approximately $6.6 billion, comprised of 13.3 million shares...

Rocket Lab Acquires Optical Support, Inc., Strengthening National Security Payload Capability

Written by Customer Service on February 26, 2026. Posted in Mergers And Acquisitions.

LONG BEACH, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in launch services and space systems, today announced it has completed the acquisition of Optical Support, Inc. (OSI), a leader in the design, engineering, and manufacturing of custom, high-precision optical and optomechanical instruments. OSI’s advanced lenses and optomechanical systems are critical enablers for national security and commercial satellites, and are key subsystems used in Rocket Lab Optical Systems’ high-performance payloads for space protection, space domain awareness, missile warning, tracking and defense. OSI delivers end-to-end solutions from concept design and prototyping to full-scale production including CNC machining, optical alignment, cleanroom assembly, and testing. As...

Brink’s Announces Fourth-Quarter and Full-Year 2025 Results

Written by Customer Service on February 26, 2026. Posted in Earnings Releases And Operating Results.

Fourth quarter revenue growth of 9% with organic growth of 5% Accelerating AMS/DRS fourth quarter organic growth to 22%Record 2025 cash generation with cash from operations of $640M and free cash flow of $436M Reduced net debt leverage to 2.7x Adjusted EBITDA RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) — The Brink’s Company (NYSE:BCO), a leading global provider of cash and valuables management, digital retail solutions (DRS), and ATM managed services (AMS), today announced fourth-quarter and full-year 2025 results. Mark Eubanks, president and CEO, said: “Supported by a strong fourth quarter, Brink’s took another significant step forward in our strategic execution in 2025. We continue to methodically transform Brink’s into a faster growing, more profitable and higher cash flow generating business supported by growth...

SoundHound AI Reports Record Annual Revenue of $169 Million, Up Nearly 100%, Forecasts Strong Growth

Written by Customer Service on February 26, 2026. Posted in Earnings Releases And Operating Results.

Closed record number of enterprise deals in Q4; Extends lead as the agentic AI partner of choice for businesses amid disruption of legacy software and servicesSANTA CLARA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) — SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice and conversational AI, today reported its financial results for the fourth quarter and full year 2025. “As traditional software faces massive AI disruption, businesses are looking to partner with AI natives that can help them achieve success in a new era. This is creating strong tailwinds for SoundHound,” said Keyvan Mohajer, CEO and Co-Founder of SoundHound AI. “Our results speak for themselves. All key profit metrics were up and in the last quarter we closed a record number of customer deals as we capitalized on the surge in demand for enterprise-grade AI.” Financial...

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Written by Customer Service on February 26, 2026. Posted in Earnings Releases And Operating Results.

2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025. “We closed out an outstanding year with a strong fourth quarter, reflecting the strength of our innovative test portfolio, disciplined execution and the dedication of the entire Castle team who continue to deliver meaningful impact for patients and clinicians every day,” said Derek Maetzold, president and chief executive officer of Castle Biosciences....

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

Written by Customer Service on February 26, 2026. Posted in Earnings Releases And Operating Results.

Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following:Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront payment and is entitled to potential milestone payments exceeding $200 million for each...

Sprout Social Announces Fourth Quarter 2025 Financial Results

Written by Customer Service on February 26, 2026. Posted in Earnings Releases And Operating Results.

Initiates Non-GAAP 30% Rule of 40 Target By the Fourth Quarter of 2027 Approximated Subscription Revenue Contribution for ≥$30K ARR Customers Grew 22% in 2025 CHICAGO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its fourth quarter ended December 31, 2025. “Our team delivered strong results in the fourth quarter, highlighted by 15% total RPO growth and strong non-GAAP profitability,” said Ryan Barretto, CEO of Sprout Social. “We are announcing a new operating goal of reaching 30% on a non-GAAP basis against a Rule of 40 framework by fourth quarter 2027 as well as making continued investments to expand our reach deeper into the $30K+ customer segment, which...

Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

Written by Customer Service on February 26, 2026. Posted in Earnings Releases And Operating Results.

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 HighlightsTotal revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of total revenueAdjusted EBITDA in the year ended December 31, 2025 was $5.0 million, compared to $22.4 million for the full year 2024Expanded...

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Written by Customer Service on February 26, 2026. Posted in Earnings Releases And Operating Results.

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing’s Syndrome to Initiate in the First Half of 2026 Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the fourth quarter and full year ended December 31, 2025. “2025 was a breakout year for...

Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook

Written by Customer Service on February 26, 2026. Posted in Earnings Releases And Operating Results.

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent HighlightsGenerated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025 Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025 Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insight Strong presence at the 2025 Human Proteome Organization World Congress with more than a dozen scientific presentations and sixteen posters...

Day: February 26, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals